Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

923 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA. Slamon DJ, et al. Among authors: chia s. Ann Oncol. 2021 Aug;32(8):1015-1024. doi: 10.1016/j.annonc.2021.05.353. Epub 2021 Jun 5. Ann Oncol. 2021. PMID: 34102253 Free article. Clinical Trial.
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.
Gelmon KA, Stewart D, Chi KN, Chia S, Cripps C, Huan S, Janke S, Ayers D, Fry D, Shabbits JA, Walsh W, McIntosh L, Seymour LK. Gelmon KA, et al. Among authors: chia s. Ann Oncol. 2004 Jul;15(7):1115-22. doi: 10.1093/annonc/mdh278. Ann Oncol. 2004. PMID: 15205207 Free article. Clinical Trial.
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM. Cheang MC, et al. J Clin Oncol. 2006 Dec 20;24(36):5637-44. doi: 10.1200/JCO.2005.05.4155. Epub 2006 Nov 20. J Clin Oncol. 2006. PMID: 17116944
Locally advanced and inflammatory breast cancer.
Chia S, Swain SM, Byrd DR, Mankoff DA. Chia S, et al. J Clin Oncol. 2008 Feb 10;26(5):786-90. doi: 10.1200/JCO.2008.15.0243. J Clin Oncol. 2008. PMID: 18258987 Review. No abstract available.
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Chia S, et al. J Clin Oncol. 2008 Apr 1;26(10):1664-70. doi: 10.1200/JCO.2007.13.5822. Epub 2008 Mar 3. J Clin Oncol. 2008. PMID: 18316794 Clinical Trial.
923 results